(3,4-二氢-1H-异色烯-1-甲基)胺盐酸盐 | 19158-90-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: (3,4-二氢-1H-异色烯-1-甲基)胺盐酸盐
• 英文名称: 2-chromanmethylamine
• 英文别名: 1-Aminomethyl-isochroman；C-isochroman-1-yl-methylamine；1H-2-Benzopyran-1-methanamine, 3,4-dihydro-；3,4-dihydro-1H-isochromen-1-ylmethanamine
• CAS: 19158-90-8
• 化学式: C₁₀H₁₃NO
• mdl: MFCD00457645
• 分子量: 163.219
• InChiKey: ILJDAFPFCCVDKU-UHFFFAOYSA-N

物化性质

• 沸点：
  110-112 °C(Press: 0.2 Torr)
• 密度：
  1.073±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  (3,4-二氢-1H-异色烯-1-甲基)胺盐酸盐 、 在 吡啶 作用下， 以 1,4-二氧六环 为溶剂， 以73%的产率得到N-[4-(isochroman-1-ylmethylcarbamoyl)phenyl]isochroman-1-carboxamide
  参考文献：
  名称：

  Synthesis of diamides from 1,4-benzodioxane-2- and isochroman-1-carboxylic acids

  摘要：

  1,4-Benzodioxane-2-carboxylic acid and isochroman-1-carboxylic acid were treated with thionyl chloride, and the resulting acid chlorides reacted with p-aminobenzoic acid in dioxane in the presence of pyridine to produce the corresponding amido acids. The latter were converted into acid chlorides which were brought into reaction with various amines to obtain a number of new diamides.

  DOI：

  10.1134/s1070428012070147
• 作为产物：
  描述：

  异色烷-1-甲腈 生成 (3,4-二氢-1H-异色烯-1-甲基)胺盐酸盐
  参考文献：
  名称：

  SAMODUROVA, A. G.;MARKARYAN, EH. A., ARM. XIM. ZH., 43,(1990) N, S. 332-336

  摘要：

  DOI：

文献信息

• [EN] TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION<br/>[FR] ANALOGUES DE LA TUBULYSINE ET LEURS PROCÉDÉS DE PRÉPARATION
  申请人：PFIZER

  公开号：WO2017134547A1

  公开（公告）日：2017-08-10

  The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.

  本发明涉及新的细胞毒性的管素类似物和衍生物，以及它们的抗体药物偶联物，以及使用它们治疗包括癌症在内的医疗状况的方法。
• Substituted Dihydroimidazoles and their Use in the Treatment of Tumors
  申请人：Chamoin Sylvie

  公开号：US20100075966A1

  公开（公告）日：2010-03-25

  The invention relates to dihydroimidazoles of formula rac-(I), wherein the radicals and symbols are as defined herein; their use as inhibitors of the interaction of the MDM2 protein with a p53-like peptide, new pharmaceutical formulations comprising said compounds, said compounds for use in the therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of proliferative diseases or for the manufacture of pharmaceutical formulations useful in the treatment of proliferative diseases that respond to modulation of the interaction of the MDM2 protein with a p53-like peptide, a pharmaceutical formulation e.g. useful in the treatment of proliferative diseases that respond to modulation of the interaction of the MDM2 protein with a p53-like peptide comprising said compound, methods of treatment comprising administration of said compounds to a warm-blooded animal, and/or processes for the manufacture of said compounds.

  该发明涉及式rac-(I)的二氢咪唑，其中基团和符号如本文所定义；它们作为MDM2蛋白与类p53肽的相互作用抑制剂的用途，包括所述化合物的新药物配方，所述化合物用于治疗温血动物，特别是人类，它们用于治疗增殖性疾病或用于制造对MDM2蛋白与类p53肽相互作用调节有响应的药物配方，例如用于治疗对MDM2蛋白与类p53肽相互作用调节有响应的增殖性疾病的药物配方，包括所述化合物，包括所述化合物的治疗方法，包括将所述化合物用于温血动物的给药，和/或所述化合物的制造方法。
• COMPOUNDS AND COMPOSITIONS AND USES THEREOF
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20180030064A1

  公开（公告）日：2018-02-01

  Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

  揭示了化合物的结构式(I)，以及含有这些化合物的药物组合物。还披露了治疗需要的受试者神经系统或精神疾病和障碍的方法。
• SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS
  申请人：EISAI R&D MANAGEMENT CO., LTD.

  公开号：US20150105370A1

  公开（公告）日：2015-04-16

  Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

  该公开的实施例涉及选择性替代喹啉化合物，其作为Toll样受体7和/或8的拮抗剂或抑制剂，并其在制药组合物中的使用，用于治疗系统性红斑狼疮（SLE）和狼疮性肾炎。
• [EN] ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME<br/>[FR] COMPOSÉS DE MODULATION DES RÉCEPTEURS ADRÉNERGIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2017197324A1

  公开（公告）日：2017-11-16

  Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with a β1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.

  提供了调节肾上腺素受体的化合物及使用方法。还提供了治疗与肾上腺素受体相关疾病或症状的方法，包括向受试者施用治疗有效量的该化合物。本公开的方面包括一种调节细胞中炎症通路的方法，例如在细胞中产生TNF-alpha。该方法可以包括将细胞与β1选择性肾上腺素受体调节化合物接触，以在细胞中选择性激活cAMP通路而不是β-arrestin通路。还提供了包含该化合物的药物组合物和试剂盒。